首页>
外国专利>
PRO-GRP AS A SURROGATE MARKER TO PREDICT AND MONITOR RESPONSE TO BCL-2 INHIBITOR THERAPY
PRO-GRP AS A SURROGATE MARKER TO PREDICT AND MONITOR RESPONSE TO BCL-2 INHIBITOR THERAPY
展开▼
机译:PRO-GRP作为替代标记,可预测和监测BCL-2抑制剂治疗
展开▼
页面导航
摘要
著录项
相似文献
摘要
A method for classifying cancer patients as eligible to receive cancer therapy with a Bcl-2 inhibitor comprising determination of the presence or absence in a patient tissue sample of levels of pro-GRP, as a surrogate marker for the presence of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon pro-GRP levels as a surrogate for the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy with a Bcl-2 family inhibitor, either as monotherapy or as part of combination therapy, and to monitor patient response to such therapy using a peripheral blood sample.
展开▼